Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 173 of 5804
-
Off-the-Shelf CAR t cells take on tough lymphomas and leukemias
Disease control Recruiting nowThis is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL, r/r B-cell NHL and CLL/SLL.
Phase: PHASE1 • Sponsor: Imugene Limited • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Immunotherapy duo before liver surgery shows promise against cancer
Disease control CompletedThe PRIME-HCC trial will assess the effects of combination treatment with nivolumab (OPDIVO) and ipilimumab (YERVOY) pre-operatively in hepatocellular carcinoma patients for whom liver resection is planned. The trial will be conducted at a small number of National Health Service …
Phase: PHASE1, PHASE2 • Sponsor: Imperial College London • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could timing of immunotherapy boost melanoma survival?
Disease control OngoingThis phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could a tooth's own pulp be used to regenerate root canals?
⭐️ CURE ⭐️ TerminatedThe purpose of this study is to develop new improved therapy for teeth that require root canals due to tooth infection or tooth inflammation. Investigators will recruit total of 50 participants from the age group 7 - 50 at the UCLA School of Dentistry Endodontic clinic. The parti…
Phase: NA • Sponsor: University of California, Los Angeles • Aim: ⭐️ CURE ⭐️
Last updated Jul 25, 2026 00:00 UTC
-
Triple threat: new drug combo aims to beat CLL in younger patients
Disease control OngoingThis phase III trial studies how well ibrutinib and obinutuzumab with or without venetoclax work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Obinutuzumab is a monoclo…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New hope for GIST patients: ripretinib takes on sunitinib in major trial
Disease control OngoingThis is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of ripretinib to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib. Approximately 426 patients will be randomized in a 1…
Phase: PHASE3 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Triple chemo attack shows promise against tough bile duct cancers
Disease control CompletedThis phase III trial studies how well gemcitabine hydrochloride and cisplatin given with or without nab-paclitaxel work in treating patients with newly diagnosed biliary tract cancers that have spread to other places in the body. Drugs used in chemotherapy, such as gemcitabine hy…
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Engineered donor cells aim to beat blood cancer without severe side effects
Disease control OngoingPatients less than or equal to 21 years old with high-risk hematologic malignancies who would likely benefit from allogeneic hematopoietic cell transplantation (HCT). Patients with a suitable HLA matched sibling or unrelated donor identified will be eligible for participation ONL…
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New clamping method could save preterm brains
Disease control CompletedDelayed cord clamping (DCC) in preterm infants results in a decrease in mortality and a trend towards fewer intraventricular haemorrhages. However, preterm infants needing immediate interventions for stabilisation or resuscitation were generally clamped immediately and excluded f…
Phase: NA • Sponsor: Leiden University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New cocktail shows promise against Tough-to-Treat colon cancer
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of the combination of study drugs encorafenib, binimetinib and cetuximab in patients who have BRAF V600 mutant metastatic colorectal cancer and have not received any prior treatment for their metastatic disease.
Phase: PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Could umbilical cord stem cells save lungs in ARDS?
Disease control OngoingAcute Respiratory Distress Syndrome (ARDS) causes the lungs to fail due to the collection of fluid in the lungs (pulmonary oedema). ARDS is common in severely ill patients in Intensive Care Units and is associated with a high mortality and a high morbidity in those who survive. A…
Phase: PHASE1, PHASE2 • Sponsor: Belfast Health and Social Care Trust • Aim: Disease control
Last updated Jun 26, 2026 14:28 UTC
-
New drug cocktail aims to outsmart resistant uterine cancer
Disease control Recruiting nowThis research study is studying a combination of targeted therapies as a possible treatment for estrogen-receptor positive (ER+) endometrial cancer. The drugs involved in this study are: * Abemaciclib (also known as Verzenio™) * Letrozole (also known as Femara®) * Metformin (al…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug cocktail aims to beat back multiple myeloma
Disease control OngoingBackground of the study: The combination of daratumumab with VRd is anticipated to further improve response rates in patients and may lead to improved long-term outcomes in newly diagnosed patients with multiple myeloma. Given this potential, and based upon the initial safety and…
Phase: PHASE3 • Sponsor: Stichting European Myeloma Network • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New hope for kids with hodgkin lymphoma: tailored chemo aims to cut toxicity
Disease control OngoingThis is a phase II study using risk and response-adapted therapy for low, intermediate and high risk classical Hodgkin lymphoma. Chemotherapy regimens will be based on risk group assignment. Low-risk and intermediate- risk patients will be treated with bendamustine, etoposide, Ad…
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to boost walking and breathing in pompe patients
Disease control CompletedThis is a phase 3 double-blind randomized study to study the efficacy and safety of intravenous ATB200 Co-administered with oral AT2221 in adult subjects with Late Onset Pompe Disease compared with Alglucosidase Alfa/placebo.
Phase: PHASE3 • Sponsor: Amicus Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 16:41 UTC
-
New targeted pill shows promise for rare blood cancer
Disease control CompletedThis is an open-label, single arm, Phase 2 study evaluating the efficacy and safety of avapritinib (BLU-285) in patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive SM (ASM), SM with associated hematologic neoplasm (SM-AHN), and mast cell leuke…
Phase: PHASE2 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New combo therapy aims to improve leukemia outcomes in older adults
Disease control Recruiting nowThis phase II trial studies how well venetoclax, cladribine, low dose cytarabine, and azacitidine work in treating patients with acute myeloid leukemia that has previously not been treated. Drugs used in chemotherapy, such as venetoclax, cladribine, and low dose cytarabine, work …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New epilepsy drug candidate aims to tame severe seizures
Disease control CompletedThis trial is intended to study the safety and effectiveness of an new anti-epileptic drug (AED) on Primary Generalized Tonic-Clonic (PGTC) Seizures. Eligible Subjects, adults and adolescents, will continue to take their usual AEDs and receive either cenobamate or placebo. Subjec…
Phase: PHASE3 • Sponsor: SK Life Science, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New immunotherapy cocktail aims to fight advanced bladder cancer
Disease control OngoingThis is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab ± tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcitabine or carboplatin + gemcitabine doublet) followed by durva…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Engineered immune cells take on tough leukemia
Disease control OngoingThis is a single center, open-label, phase 1 study to determine the safety and feasibility of infusing CART22-65s with or without huCART19 after administration of lymphodepleting chemotherapy in adult patients with relapsed or refractory B-ALL.
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC